Epidarex Capital

Epidarex Capital is a transatlantic venture capital firm specializing in early-stage, high-growth life science and health technology companies in under-ventured markets. The firm focuses on providing risk capital to young companies, including spin-outs from leading research institutions in both established and emerging life science hubs. Epidarex Capital's international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market.

The firm's investment strategy emphasizes transformative opportunities in biotechnology, medical devices, pharmaceuticals, personalized medicine, diagnostics, healthcare IT, and healthcare services. Epidarex Capital typically leads or co-leads investments in company funding rounds totaling up to £10 million, often syndicating with other funds. The firm places a particular emphasis on innovations spun out of universities, aiming to address major unmet needs in the global healthcare market.

Epidarex Capital's diverse investor base includes pharmaceutical companies, top research universities, development agencies, and financial institutions. The firm's close working relationship with leading research universities provides access to some of the most innovative healthcare start-ups, including those specializing in novel drug development. This collaborative approach enables Epidarex Capital to build highly competitive businesses and support the growth of life science companies across the United States and the United Kingdom.